AIM: To investigate the in vitro effect of entecavir (ETV on the function of dendritic cells (DCs) derived from chronic hepatitis B (CHB) patients. METHODS: Mononuclear cells were isolated from peripheral blood of pat...AIM: To investigate the in vitro effect of entecavir (ETV on the function of dendritic cells (DCs) derived from chronic hepatitis B (CHB) patients. METHODS: Mononuclear cells were isolated from peripheral blood of patients with CHB. DCs wer incubated with RPMI-1640 medium supplemented wit fetal bovine serum, IL-4, granulocyte-macrophag colony-stimulating factor (GM-CSF). DCs were treate with or without ETV on the fourth day. Cell surfac molecules, including CD1a, CD80, CD83 and HLA-DR were assessed by flow cytometry. Concentrations of IL- and IL-12 in the supernatant were assayed by enzyme linked immunosorbent assay (ELISA). The ability of th generated DCs to stimulate lymphocyte proliferation wa observed. RESULTS: Compared with CHB control group, th expression levels of CD1a (29.07 ± 3.20 vs 26.85 ± 2.80 CD83 (25.66 ± 3.19 vs 23.21 ± 3.10), CD80 (28.00 ± 2.7 vs 25.75 ± 2.51) and HLA-DR (41.96 ± 3.81 vs 32.20 ± 3.04) in ETV-treated group were higher (P < 0.05). ETV treated group secreted significantly more IL-12 (157.6 ± 26.85 pg/mL vs 132.60 ± 22.00 pg/mL (P < 0.05) an had a lower level of IL-6 in the culture supernatant (83.0 ± 13.88 pg/mL vs 93.60 ± 13.61 pg/mL, P < 0.05) tha CHB control group. The ability of DCs to stimulate th proliferation of allogeneic lymphocytes was increase in ETV-treated group compared with CHB control grou (1.53 ± 0.09 vs 1.42 ± 0.08, P < 0.05).CONCLUSION: Entecavir can enhance the biological activity of DCs derived from CHB patients.展开更多
文摘AIM: To investigate the in vitro effect of entecavir (ETV on the function of dendritic cells (DCs) derived from chronic hepatitis B (CHB) patients. METHODS: Mononuclear cells were isolated from peripheral blood of patients with CHB. DCs wer incubated with RPMI-1640 medium supplemented wit fetal bovine serum, IL-4, granulocyte-macrophag colony-stimulating factor (GM-CSF). DCs were treate with or without ETV on the fourth day. Cell surfac molecules, including CD1a, CD80, CD83 and HLA-DR were assessed by flow cytometry. Concentrations of IL- and IL-12 in the supernatant were assayed by enzyme linked immunosorbent assay (ELISA). The ability of th generated DCs to stimulate lymphocyte proliferation wa observed. RESULTS: Compared with CHB control group, th expression levels of CD1a (29.07 ± 3.20 vs 26.85 ± 2.80 CD83 (25.66 ± 3.19 vs 23.21 ± 3.10), CD80 (28.00 ± 2.7 vs 25.75 ± 2.51) and HLA-DR (41.96 ± 3.81 vs 32.20 ± 3.04) in ETV-treated group were higher (P < 0.05). ETV treated group secreted significantly more IL-12 (157.6 ± 26.85 pg/mL vs 132.60 ± 22.00 pg/mL (P < 0.05) an had a lower level of IL-6 in the culture supernatant (83.0 ± 13.88 pg/mL vs 93.60 ± 13.61 pg/mL, P < 0.05) tha CHB control group. The ability of DCs to stimulate th proliferation of allogeneic lymphocytes was increase in ETV-treated group compared with CHB control grou (1.53 ± 0.09 vs 1.42 ± 0.08, P < 0.05).CONCLUSION: Entecavir can enhance the biological activity of DCs derived from CHB patients.
